BioTime touts early results of research on iPS cell technology

03/16/2010 | Wall Street Journal, The · Bloomberg Businessweek

Preliminary data show that one of the six lines of induced pluripotent stem cells being studied by BioTime had enough of the protein telomerase to reverse cellular aging, making the iPS cell line a potential alternative to embryonic stem cells. BioTime CEO Michael West expressed optimism that the company is "years away -- not decades away -- from clinical trials."

View Full Article in:

Wall Street Journal, The · Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ